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Abstract
Background: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate,
actual data related to the experience of giving individual results back, and the impact these results may have on
clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome
Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified;
and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and
opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful
for others developing their own policies.
Methods: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal
DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic
germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance
genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated
and classified according to international guidelines. Variants were considered actionable if clinical utility was established,
with regard to prevention, diagnosis, prognostication and/or therapy.
Results: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in
silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework,
representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR.
Conclusion: Returning research results within the context of large-scale genomics research is a labour-intensive, highly
variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience
a clinical difference as a result of returning individual results is currently low.
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Background
The advent of high throughput and more rapid genomic
technologies offers an extraordinary opportunity to
further our understanding of the contribution of gen-
etic variation in complex diseases such as cancer.
Considerable international efforts spanning the past
decade have mapped the genomes of large cohorts of
cancer patients and provided insights into prevention,
early detection and treatment of cancer [1, 2]. These
efforts continue to accelerate rapidly on a technical,
scientific and methodological level with increased capacity
and breadth of cases studied. Such work is shedding new
light on what effect these genetic events have on clinical
phenotypes, such as how specific genetic features relate to
patterns of metastasis and treatment response. Although
comprehensive catalogues of mutations across a wide
range of cancers has provided us with foundational
knowledge, considerable challenges remain with respect
to implementing this knowledge within existing clinical
frameworks.
Whether it is appropriate to give individually relevant
research results back to participants in research studies,
or so-called return of individual results (RoR), has emerged
broadly as a complex and contentious issue that remains
fervently debated [3–8]. Nevertheless, several jurisdictions
have agreed that genomic results, which meet scientifically
accepted criteria, should be disclosed through appropri-
ately developed and approved frameworks within a re-
search context [9–11]. In addition, it has been reported in
the cancer setting that participants express great desire to
have important research results reported to them directly
and also to their relatives and spouses if results become
available after the participant is deceased [12]. The myriad
commentaries and reports describing approaches to RoR
have focused on key upstream components such as the in-
terpretation and classification of variants for clinical signifi-
cance, the frequency and types of findings that should be
returned, and with whom the responsibility of returning re-
sults lies. Despite the debate, actual data related to the ex-
perience of giving individual results back, and the impact
these results may have on clinical care and health out-
comes, are sorely lacking. Furthermore, it has consist-
ently been commented that policy for RoR in research
settings is required and there is a call for real ap-
proaches and outcomes of RoR to be widely shared,
compared and evaluated [3, 9].
The RoR process is further complicated within large-
scale genome research where the premise of such re-
search involves the sharing of samples and data across
international borders and broad accessibility of these
large datasets to the research community. The diverse
legal, ethical and cultural norms implicit in international
studies requires careful navigation across different juris-
dictions and therefore harmonisation is a vital goal.
Through the prospective observational cohort design
of the Australian Pancreatic Cancer Genome Initiative
(APGI), we present our real-world experience of the
RoR process in a contemporary research setting, detail-
ing the trajectory from recruitment to clinical utilisation.
Using these data, we aim to: (1) delineate the pathway
back to the patient where actionable research data were
identified in the germline; and (2) report the clinical util-
isation of individual results returned. Through this we
will explore the barriers and opportunities associated
with a comprehensive process of RoR in large-scale
international genomic research and provide a commentary
on how the pragmatic approach adopted in Australia can
be potentially generalised to other jurisdictions.
Methods
Study population
Patients were recruited through participating institutions
of the APGI between 2009 and 2013 (http://www.
pancreaticcancer.net.au) as part of the International Can-
cer Genome Consortium (ICGC; http://www.icgc.org).
Samples were contributed by third-party international col-
laborators as part of the Pancreatic ICGC effort. Prospect-
ive participants were provided with information that
detailed the possibility of finding genetic variations that
may be of relevance to them or their family members and
that such findings may not be limited to their diagnosis of
pancreatic cancer (PC). The consent process allowed par-
ticipants the choice to ‘opt in’ to have individual results
communicated, and given the short survival of many indi-
viduals with PC, the choice of to whom else they may be
communicated. Ethical approval was obtained from the
human research ethics committee at each participating
site. All participants provided written informed consent
upon entry to the study.
Pathway for RoR process
The Australian National Statement on ethical conduct in
Human Research (2007) section 3.5.1 states ‘Where re-
search may discover or generate information of potential
importance to the future health of participants, or their
blood relatives, researchers must prepare and follow an
ethically defensible plan to disclose or withhold that in-
formation’. Given this obligation in Australia, a previ-
ously described framework was utilised in this study
[13], which employs a context-dependent approach and
enacts a category-based system for the characterisation
of research findings as endorsed by others [14, 15]. The
central components of the framework are informed
consent, clinical utility, multidisciplinary (MDT) review,
communicability and follow-up. Communicability con-
siders the practicality of communicating results, the cir-
cumstances of the participant and treating clinician and
how best the results could be communicated. Wherever
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allowable, results are to be communicated to the clinical
care provider or treating medical team for their consider-
ation (Additional file 1). The overall process is outlined in
Fig. 1. Candidate genes were selected after review of the
published literature and the Online Mendelian Inheritance
in Man (OMIM) database. The list (n = 130, Additional file
2) includes genes with established risk for PC, genes with a
cancer-related syndrome or a well-characterised solid organ
or haematological cancer phenotype [6, 16, 17]. Considering
both the practical and ethical aspects, the focus was strictly
on cancer-related genes as these were related to the research
indication. This framework was approved by each institu-
tional Human Research Ethics Committee and data re-
corded by research personnel at each step (Fig. 1).
Interpretation and classification of variants
The genomic coordinates of germline variants were an-
notated for gene consequence with ensembl v75 [18].
Fig. 1 Return of results workflow
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The effect of missense variants was predicted using
polyphen2 [19], SIFT [20], CADD [21], VEST3 [22],
alignGVGD [23], MutationTaster [24], phyloP [25] and
phastCons [26]. Allele frequency in the general popula-
tion was obtained from the 1000 Genomes Project
(http://www.internationalgenome.org/), Exome Aggre-
gation Consortium (http://exac.broadinstitute.org/
about) [27] and dbSNPv141 (http://www.ncbi.nlm.nih.-
gov/SNP). The results were compiled and variants
ranked using a five-tiered schemata adapted from inter-
national guidelines [28, 29] (class 5 = pathogenic, class
4 = likely pathogenic, class 3 = uncertain significance,
class 2 = probably no pathogenicity, 1 = no pathogen-
icity, Additional file 3). Variants class 3 and above were
further examined in the published literature and inher-
ited mutation databases including ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar), HGMD professional
[30], OMIM and locus-specific databases (InSiGHT
[28] and Leiden open variation databases [31]) before
being assigned a final consensus class. Variants charac-
terised as Class 4 or 5 (pathogenic or likely pathogenic)
in genes with established clinical utility were triaged to
a Molecular Multidisciplinary Team Meeting
(MolMDT). The full body of variant evidence was pre-
sented to the MolMDT for evaluation and considered
established clinical guidelines. These were then
reviewed in the context of the individual patient and a
formal report issued documenting evidence-based
decision-making (Additional file 4). All cases involved
consultation with clinical teams or collaborators prior
to dissemination, for guidance where needed and to
offer the opportunity to engage with the MolMDT dis-
cussion. Participants and clinical teams were followed
up in accordance with standard APGI clinical protocols
and at intervals post result communication (Fig. 1).
Results
A total of 463 patients with clinically sporadic PC were
recruited to the study between 2009 and 2013. Of the
participants, 97.8% (n = 453) indicated via the consent
process that they wished to have results returned to
them or to their designee. Of the cases, 392 (84%) satis-
fied project-specific technical and quality essentials, such
as minimum sample weight and tumour cellularity,
permitting entry into the sequencing pipeline. We per-
formed whole-genome (n = 184) and exome (n = 208)
sequencing of matched tumour-normal DNA pairs
from eligible patients to an average depth of 65×
(tumour) and 35× (germline) under conditions previ-
ously described by this group [1, 32, 33]. No patient
had an established hereditary cancer syndrome at en-
rolment. The median age at diagnosis was 67 years and
the age range was 33–90 years. A total of 48,904 germ-
line variants were identified, of which 2356 were
unique in 130 candidate cancer predisposition genes.
Participants had a median of 205 variants each, in the
range of 2–633 variants each across the cohort. A total
of 568 (24%) variants were ranked as class 3 or above
and underwent additional review to assess presence in
published literature and inherited mutation databases
[30, 34]. Fifty-eight variants (2.5%) in 32 genes remained
classified as pathogenic (Class 4 or 5) and were reported
in 65 different patients. Upon final classification, 24 vari-
ants in genes with established clinical utility were reviewed
at the MolMDT. Review, work up and discussion of each
variant took an estimated average of 5 working hours of
personnel time. Following MolMDT review 19 pathogenic
variants reported in 20 cases were recommended for re-
turn. The characteristics of cases returned are described
in Table 1. Cases with available sample (n = 14) proceeded
to independent validation through an accredited labora-
tory issuing a clinical report and all mutations were suc-
cessfully validated. In cases where findings could not be
validated as no residual germline tissue was available, pre-
liminary results and recommendations from the MolMDT
were returned to collaborators to pursue. In keeping with
the low survival rate of PC, ten patients (50%) were de-
ceased at the time results were available, four patients
(20%) were alive with disease and/or undergoing active
treatment or monitoring for their disease, five (25%) pa-
tients were discharged from primary specialist care and
one (5%) was lost to follow-up.
Observing the guidelines in the established RoR path-
way results were disseminated considering context as
follows: directly to the principal collaborator where sam-
ples were contributed by third parties (n = 9); through
clinical teams where patients were undergoing active
treatment or monitoring (n = 6); direct to patient or fam-
ily members via letter where patients were deceased or
no longer receiving active specialist care (n = 5).
Upon follow-up to date, seven cases (35%) have been
clinically actioned, defined as consultation and ongoing
management within a clinical genetics service, and/or
having an influence on clinical decision-making for ac-
tive clinical care. Specifically, two cases with BRCA2
mutations were switched to third-line therapy with mito-
mycin C. The time lapse from result dissemination to
action was in the range of 59–626 days.
The residual cases not defined as actioned were cate-
gorised as follows: no allowance for RoR in collaborator
policy (n = 8); clinical decision not to pursue (n = 2); and
non-response to communication (n = 3).
Discussion
In this report, we describe the longitudinal process of
returning germline research results in a cancer context
via established mechanisms. These data allow us to illus-
trate a range of clinical and infrastructural challenges,
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and practicability, best explored along the complex con-
tinuum of RoR. It is to the best of our knowledge the
first to report this within a contemporary cancer genom-
ics setting over a protracted period of time.
Overall, 19 pathogenic variants in eight candidate can-
cer genes in 20 patients were deemed actionable. This
represents an actionable finding rate of 5.1% (n = 392) in
our cohort. Seven cases were actioned, resulting in
1.78% (n = 392) of the cohort experiencing a clinical
benefit from returning research results. Although this
number appears low, it is important to note that 63% (n
= 7/11), of participants or family members who actually
received information, actioned the finding. This is sig-
nificant given that PC has a high rate of mortality and
that 50% of participants were deceased at the time of re-
turn. This high rate of action establishes the importance
of RoR to participants and family members and the po-
tential benefit it may present.
Reports of actionable finding rates have been shown to
be diverse and dependant on the disease setting and spe-
cific genes assessed [35, 36]. Moreover, these actionabil-
ity rates are often theoretically based and defined using
variant classification in absence of detail surrounding
clinical utility and communicability in the context of the
individual patient.
In our experience, the overall process of managing
RoR was a resource-demanding activity. The require-
ments for developing extensive infrastructure required
for evaluating genetic findings, disseminating results and
performing detailed follow-up was labour-intensive,
costly and time-consuming. It also required the input
and coordination of a MDT consisting of both research
and clinical personnel, including but not limited to:
genetic pathologists; clinical geneticists; oncologists;
surgeons; genetic counsellors; and bioinformaticians.
Significant time and cost considerations were experienced
with approximately 5 person-hours on average to review
each variant prior to MolMDT, discussion within the
MolMDT, independent confirmatory testing, re-contact of
next of kin, and recording and disseminating paperwork.
Moreover, many of these costs could not be accurately
considered from the outset due to lack of guidelines on
how to formally manage such a process at the time and
the intrinsic unpredictability of RoR. Budgetary and
personnel requirements for RoR need to be considered
within the context of the individual project at the design
stage alongside those for sequencing and analysis.
Due to the diversity of results and of individual patient
situations, it was imperative to allow flexibility in the
method of communication. Forty percent of cases where
notification was by written letter were actioned and lower
rates of response to letters is reported [37, 38]. Letters to
next of kin were employed as the mode of communication
where participants were deceased (55% of the cohort,
Table 1), as this represented the only remaining and appro-
priate outlet to communicate with them. Letters may have
been emotionally confronting when received by the next of
kin in these situations, especially if they were unaware of
the research. Returning results to relatives of deceased par-
ticipants is not currently widespread practice [39], and
while procedures were in place for deceased participant
cases, it is recommended that participants are made aware
of this possibility and asked to discuss it with their relatives
if possible while alive. Australian Privacy law [40] does not
address the use of information from deceased persons.
However, an important amendment to the privacy act [41]
allows for communication with family members without
consent of a person under their care if a medical practi-
tioner feels there is a risk of harm to them arising from
knowledge about that person. Greater action rates (66%,
Table 1) were experienced where treating clinicians were
notified and the participants and or family were informed
face-to-face by the clinical team. This existing relationship
allows for these often-complex discussions to take place in
an environment where information can be reinforced and
relevance put into perspective for clinical decision-making.
Engaging treating clinicians in the MolMDT process prior
to dissemination can facilitate a smooth transition into ne-
cessary clinical pathways or therapeutic actions, as they are
armed with paperwork necessary for referrals of further
genetic testing or other relevant supporting information. In
summary, our experiences demonstrate that result dissem-
ination needs to be considered in the context of the partici-
pant and their family at that specific point in time.
Returning results discovered through the work of inter-
national scientific research consortia adds a layer of com-
plexity not routinely experienced by research studies in
the past. There is currently no guidance for international
consortia, and in most instances the responsibility for RoR
is delegated to the local level through consortia developed
policies. In our study, 45% of actionable cases were from
international collaborators (Table 1) and the applicability
of our RoR process was restricted due to collaborators
local polices, consent parameters and country-specific
guidelines. Only one case could be confirmed as actioned.
Our experiences highlight the need for a level of harmon-
isation of RoR approaches globally. Furthermore, the value
and suitability of individually developed consortia-level
policies as the primary management tool for RoR will in-
evitably be bought into question as genome sequencing
on a large scale continues to advance. Future approaches
could include integration of consortium level oversight
while allowing for necessary local autonomy.
Despite the vast amount of effort on review and dis-
semination of results, the overall number of patients
who experienced a clinical benefit from the return of re-
search results in our cohort was low. Furthermore, this
low action rate was experienced despite the research
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being associated with a diverse team of scientific and
clinical specialties, regular participant follow-up, high
participant and community engagement, a considered
budget and experience with producing high quality
datasets. Moreover, these findings were mostly related
to well-established cancer genes routinely managed in
clinical care. Our study highlights how clinicians may
be expected to respond to genomic information they
had not initiated, but are receiving directly or indir-
ectly through research targeting the tumour genome.
Clinicians need to be equipped and empowered to use
genomic information in routine practice and concerns
about genetic literacy and preparedness for genome
sequencing has been voiced by clinicians themselves
[42, 43]. Further complexities arise when pathogenic
mutations are detected outside of a typical disease
phenotype where clear evidence based guidelines for
management are less established, as illustrated by the
clinical decision not to act in two cases (Table 1). Re-
designing a pathway that enables RoR as part of the
health system will enhance the interaction across the
continuum of research and clinical care and help ad-
dress the feasibility and economic issues and in turn
support sustainability.
While case studies, commentaries and opinion
pieces have been useful to date, the RoR process is not
static. Application of RoR requires a dynamic longitu-
dinal view of the process incorporated with outcomes.
Effectively navigating the RoR process is a current glo-
bal challenge and significant investment has been re-
cently injected to analyse the ethical, social and legal
effects of genomic information [44]. Reports of empir-
ical data are crucial to ascertain the range of benefits
and harms of RoR. Plenty of obstacles and challenges
no doubt remain, as returning important research in-
formation to participants is a young pursuit. The sig-
nificant investment in overcoming the challenges of
sequencing and analysis on a large scale needs to be
mirrored in RoR, as the technology of genomic se-
quencing itself moves into clinical care, application of
important research results is fundamental to transla-
tional medicine.
Conclusion
Of our cohort, 5.1% had results that were theoretically
actionable. However, only seven cases were actioned,
resulting in 1.78% of the cohort of 392 participants de-
riving clinical benefit from RoR. Despite this low num-
ber, 63% of those who received information acted upon
this information, demonstrating that RoR stands to be of
significant value to participants and family members if
we can work to steadily remove the clinical and proced-
ural barriers to implementation.
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